Boston Scientific (BSX) EBT (2009 - 2026)

Boston Scientific has disclosed EBT across 18 years of filings, most recently posting $1.1 billion for Q2 2026.

• In Q2 2026, EBT rose 12.65% year-over-year to $1.1 billion; the TTM figure through Jun 2026 stood at $3.9 billion (up 28.7% YoY), while the FY2025 annual figure was $3.4 billion, up 48.33% from the prior year.
• EBT came in at $1.1 billion for Q2 2026 at Boston Scientific, down from $1.2 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $1.2 billion in Q1 2026 to a low of $156.0 million in Q1 2022.
• Average EBT over 5 years is $612.0 million, with a median of $596.5 million recorded in 2024.
• The largest YoY upside for EBT was 232.77% in 2022 against a maximum downside of 52.0% in 2022.
• Over 5 years, EBT stood at $396.0 million in 2022, then increased by 27.53% to $505.0 million in 2023, then gained by 15.84% to $585.0 million in 2024, then advanced by 19.66% to $700.0 million in 2025, then jumped by 51.43% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent EBT figures were $1.1 billion in Q2 2026, $1.2 billion in Q1 2026, and $700.0 million in Q4 2025.